Sandoz, Samsung and Amgen launch AmAb products in the EU

Oct 15, 2018

Sandoz, Samsung and Amgen launch their biosimilar adalimumab products (Hyrimoz®, Imraldi® and Amgevita®) pursuant to the terms of their IP licences with AbbVie.  Mylan also has EMA approval (but no AbbVie EU IP licence) but has indicated an intention to launch their biosimilar Hulio® on or after 16 October.  Similarly Boehringer has no IP licence, but we have no indication of BI’s launch plans for approved Cyltezo®

Print Page Mail Article